Obligations Related to Manufacturing. In the case of termination by Roche according to Sections 20.2.1, 20.2.2 or 22.8 or by GBT under Section 20.2.3 (other than for safety reasons), if Roche provides a timely Continuation Election Notice as provided in Section 20.3.2, then GBT shall [***]; and (iii) use Commercially Reasonable Efforts to [***].
Obligations Related to Manufacturing a) Clinical Supplies In the case of termination by BPM according to Section 21.2.1, Section 21.2.2 or Section 21.2.5 or by Roche under Section 21.2.4, if BPM elects to develop the Reversion Products, Roche shall transfer all existing and available clinical material to BPM at […***…] and upon the request of BPM. After such transfer is effectuated, (i) Roche shall have no obligation to perform any additional activities concerning the clinical supplies (e.g., retesting, analyses) and (ii) BPM shall assume all liability for the use of such material. At BPM’s request, immediately after notice of termination, Roche will cooperate to accelerate the transfer of the technology necessary to manufacture the clinical material to BPM or its designee as soon as practicable, and Roche will leverage its relationships with CROs to enable BPM to assume responsibility for manufacturing.
Obligations Related to Manufacturing. If (i) Roche has provided notice to River Vision that Roche wishes to continue the development and/or commercialization of the Product, and (ii) Product is then being manufactured, then, upon the request of Roche, River Vision shall use Commercially Reasonable Efforts to manufacture and supply (or have manufactured or supplied, as the case may be) Product to Roche for a period which shall not exceed [***] months from the effective date of the termination of this Agreement at a price to be agreed by the parties in good faith. Roche shall use Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of termination.
Obligations Related to Manufacturing. If a Product is marketed in any country in the Territory on the date either Party provides a notice of termination of this Agreement (other than a termination pursuant to Section 19.2.4), then upon the request of Regeneron, Roche shall manufacture and supply such Product to Regeneron at the then-current Minimum Committed Roche Capacity prior to expiration or termination for a period that shall not exceed [* * *] from the end of the Agreement Term at [* * *], then [* * *]; (b) if this Agreement is terminated by Roche pursuant to Section 19.2.1, then Roche shall not be obligated to supply Product to Regeneron under this Section 19.3.2.2. Without limiting Roche’s obligation under Section 19.3.1, Regeneron shall use Commercially Reasonable Efforts to take over the manufacturing as soon as practicable after termination of this Agreement; and (c) if this Agreement is terminated by Roche for an Alternative Third Party Product pursuant to Section 19.2.5, and, during the [* * *] post-termination supply period, Roche enters into an agreement with the applicable Third Party with respect to such Alternative Third Party Product and, as a result, will have insufficient capacity to manufacture such Alternative Third Party Product and the Product at the Roche Manufacturing Facilities, then Roche may reduce its supply of the Product to Regeneron as needed to manufacture such Alternative Third Party Product upon [* * *] prior written notice (which notice may be delivered at any time concurrently with or after Roche executing the agreement with the applicable Third Party with respect to such Alternative Third Party Product). During the post-termination supply period, Roche shall cooperate with Regeneron to facilitate a smooth and orderly transition of manufacturing of the Product to Regeneron or its designee. Upon expiration of the post-termination supply period, Roche shall, upon Regeneron’s request, sell to Regeneron all or any requested portion of its inventory, if any, of Drug Substance, Drug Product and Finished Product remaining after fulfillment of Regeneron’s orders during the post-termination supply period at Roche’s Fully Burdened Manufacturing Cost.
Obligations Related to Manufacturing. (a) Clinical Supplies In the case of termination by Roche according to Sections 20.3, 20.4 or 22.5 or by PEGA1 under Section 20.3 or 20.5, if Roche elects to develop the Product(s), upon the request of Roche, PEGA1 shall transfer all existing and available clinical material to Roche and Roche shall reimburse PEGA1 for this material at PEGA1’s fully burdened manufacturing cost, provided however that PEGA1 shall procure the supply for the ongoing study(ies) until the transfer of the respective study and/or supply has been completed. PEGA1 shall use Commercially Reasonable Efforts to transfer the manufacturing and supply processes and technologies to Roche or a Third Party defined by Roche as soon as possible after the effective date of termination at PEGA1 cost and provide Roche corresponding support free of charge until such processes and technologies have been fully established at Roche or at the Third Party defined by Roche.
Obligations Related to Manufacturing. In the case of any termination or expiration of this Agreement, if a Licensed Product has been sold in the Field in the Territory within the [*] months prior to, or at any time following, the date of the notice of termination of this Agreement, then, upon the request of Cempra, and in addition to Toyama’s obligations and Cempra’s rights under Section 12.9(a), 12.9 (b), and 12.9(c), Toyama shall, if and as requested by Cempra, manufacture and supply Licensed Product to Cempra for a period which shall not exceed [*] months from the effective date of termination of this Agreement at a Commercially Reasonable price, and on Commercially Reasonable other terms, as shall be agreed by the Parties in good faith, provided that, if the Parties cannot reach agreement on such price and terms within [*] Calendar Days of such termination and Cempra provides written notice, within [*] Calendar Days of the expiration of such [*] Calendar Day period electing to resolve the price and/or other terms of such supply pursuant to Section 15, such price and terms shall be determined pursuant to Section 15. Cempra shall use Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of termination.
Obligations Related to Manufacturing. If a Product is marketed in any country of Territory on the date of the notice of termination of this Agreement by ROCHE pursuant to Section 20.2.1 or by EVOTEC pursuant to Section 20.2.2, upon the request of Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934. ROCHE, EVOTEC shall manufacture and supply Product to ROCHE for a period which shall not exceed eighteen (18) months from the effective date of the termination of this Agreement at a price to be agreed by the Parties in good faith. ROCHE shall use Commercially Reasonable Efforts to take over the manufacturing as soon as possible after the effective date of termination.
Obligations Related to Manufacturing a) Clinical Supplies In the case of termination by Roche according to Sections 19.2, 19.3 or 21.8 or by CinCor under Section 19.4, if Roche elects to develop the Product(s), upon the request of Roche, CinCor shall transfer all existing and available clinical material to Roche and Roche shall reimburse CinCor for this material at [***], provided however that CinCor shall procure the supply for the ongoing study(ies) until the transfer of the respective study and/or supply has been completed. CinCor shall use Commercially Reasonable Efforts to transfer the manufacturing and supply processes and technologies to Roche or a Third Party defined by Roche as soon as possible after the effective date of termination and provide Roche corresponding support until such processes and technologies have been fully established at Roche or at the Third Party defined by Roche.
Obligations Related to Manufacturing. If (i) Roche has provided Company a timely Continuation Election Notice, and (ii) Product is then being manufactured, then, upon the request of Roche, Company shall use reasonable efforts to manufacture and supply (or have manufactured or supplied, as the case may be) Product to Roche for a period that shall not exceed [***] from the effective date of the termination of this Agreement at a price to be agreed by the Parties in good faith. Rxxxx shall use reasonable efforts to take over the manufacturing as soon as possible after the effective date of termination.
Obligations Related to Manufacturing a) Clinical Supplies In the case of termination by Roche according to Sections 18.2.1 or 18.2.2 or by Millendo under Section 18.2.3, if Roche elects to develop the Product(s), upon the request of Roche, Millendo shall transfer all existing and available clinical material to Roche and Roche shall reimburse Millendo for this material at Millendo’s fully burdened manufacturing cost, plus [***] percent ([***]%), provided however that Millendo shall procure the supply for the ongoing study(ies) until the transfer of the respective study and/or supply has been completed. Millendo shall, subject to reimbursement by Roche of its reasonably incurred external costs , use Commercially Reasonable Efforts to transfer the manufacturing and supply processes and technologies to Roche or a Third Party defined by Roche as soon as possible after the effective date of termination and provide Roche corresponding support until such processes and technologies have been fully established at Roche or at the Third Party defined by Roche.
